The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors.
Carcinoid
CgA
Liquid biopsy
NETest
Neuroendocrine
Journal
Advances in medical sciences
ISSN: 1898-4002
Titre abrégé: Adv Med Sci
Pays: Netherlands
ID NLM: 101276222
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
24
05
2019
revised:
19
09
2019
accepted:
18
10
2019
pubmed:
17
12
2019
medline:
3
2
2021
entrez:
17
12
2019
Statut:
ppublish
Résumé
There are few effective biomarkers for neuroendocrine tumors. Precision oncology strategies have provided liquid biopsies for real-time and tailored decision-making. This has led to the development of the first neuroendocrine tumor liquid biopsy (the NETest). The NETest represents a transcriptomic signature of neuroendocrine tumor (NETs) that captures tumor biology and disease activity. The data have direct clinical application in terms of identifying residual disease, disease progress and the efficacy of treatment. In this overview we assess the available published information on the metrics and clinical efficacy of the NETest. Published data on the NETest have been collated and analyzed to understand the clinical application of this multianalyte biomarker in NETs. NETest assay has been validated as a standardized and reproducible clinical laboratory measurement. It is not affected by demographic characteristics, or acid suppressive medication. Clinical utility of the NETest has been documented in gastroenteropancreatic, bronchopulmonary NETs, in paragangliomas and pheochromocytomas. The test facilitates accurate diagnosis of a NET disease, and real-time monitoring of the disease status (stable/progressive disease). It predicts aggressive tumor behavior, identifies operative tumor resection, and efficacy of the medical treatment (e.g. somatostatin analogues), or peptide receptor radionuclide therapy (PRRT). NETest metrics and clinical applications out-perform standard biomarkers like chromogranin A. The NETest exhibits clinically competent metrics as an effective biomarker for neuroendocrine tumors. Measurement of NET transcripts in blood is a significant advance in neuroendocrine tumor management and demonstrates that blood provides a viable source to identify and monitor tumor status.
Identifiants
pubmed: 31841822
pii: S1896-1126(19)30012-4
doi: 10.1016/j.advms.2019.10.002
pmc: PMC7453408
mid: NIHMS1615963
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
18-29Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest Mark Kidd is an employee of Wren Laboratories. Somer Matar formerly worked at Wren Laboratories. Irvin M. Modlin and Ignat Drozdov are consultants to Wren Laboratories.
Références
Ann Surg. 2010 Feb;251(2):307-10
pubmed: 20010089
Lancet Oncol. 2015 Sep;16(9):e435-e446
pubmed: 26370353
J Gastrointest Surg. 2016 Jan;20(1):180-8; discussion 188
pubmed: 26394880
Eur J Nucl Med Mol Imaging. 2015 Aug;42(9):1341-52
pubmed: 25947577
HPB (Oxford). 2019 May;21(5):612-618
pubmed: 30366884
Oncotarget. 2015 Feb 10;6(4):1920-41
pubmed: 25605240
Eur J Cardiothorac Surg. 2018 Mar 1;53(3):631-639
pubmed: 29145657
Virchows Arch. 2017 May;470(5):545-552
pubmed: 28213807
Science. 2012 Jun 15;336(6087):1388-90
pubmed: 22700908
Trends Pharmacol Sci. 2019 Mar;40(3):172-186
pubmed: 30736982
J Clin Endocrinol Metab. 2011 Dec;96(12):3741-9
pubmed: 21994954
J Clin Oncol. 2008 Jun 20;26(18):3063-72
pubmed: 18565894
Am J Gastroenterol. 2015 Aug;110(8):1223-32
pubmed: 26032155
J Clin Endocrinol Metab. 2019 Mar 1;104(3):867-872
pubmed: 30358858
Arch Med Sci. 2016 Feb 1;12(1):1-9
pubmed: 26925113
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Neuroendocrinology. 2019;108(3):219-231
pubmed: 30654372
Best Pract Res Clin Endocrinol Metab. 2016 Jan;30(1):59-77
pubmed: 26971844
Endocr Relat Cancer. 2007 Jun;14(2):473-82
pubmed: 17639060
Curr Opin Endocrinol Diabetes Obes. 2016 Feb;23(1):28-37
pubmed: 26627724
Cancer Treat Rev. 2018 Nov;70:209-222
pubmed: 30292979
Cell Mol Gastroenterol Hepatol. 2015 Jan 12;1(2):131-153
pubmed: 28210673
J Clin Endocrinol Metab. 2015 Nov;100(11):E1437-45
pubmed: 26348352
Endocr Relat Cancer. 2014;21(6):R445-60
pubmed: 25296914
Eur J Endocrinol. 2011 Oct;165(4):589-95
pubmed: 21775499
N Engl J Med. 1984 Sep 20;311(12):764-70
pubmed: 6472366
Cancer. 2008 Jul 1;113(1):5-21
pubmed: 18473355
Endocr Connect. 2014 Dec;3(4):215-23
pubmed: 25316294
Hum Pathol. 2018 Sep;79:109-115
pubmed: 29763717
PLoS One. 2013 May 15;8(5):e63364
pubmed: 23691035
Cancer Inform. 2011;10:175-83
pubmed: 21695068
Sci Rep. 2018 Nov 15;8(1):16863
pubmed: 30442902
Endocr Relat Cancer. 2018 Jan;25(1):R11-R29
pubmed: 29066503
BMC Genomics. 2014 Jul 15;15:595
pubmed: 25023465
J Thorac Dis. 2017 Nov;9(Suppl 15):S1458-S1473
pubmed: 29201449
Neuroendocrinology. 2016;103(2):117-8
pubmed: 26731186
Neuroendocrinology. 2013;97(1):99-112
pubmed: 22508344
Target Oncol. 2012 Jun;7(2):127-33
pubmed: 22585430
Ann Surg Oncol. 2010 Sep;17(9):2427-43
pubmed: 20217257
J Clin Oncol. 2007 May 1;25(13):1753-9
pubmed: 17470865
Neuroendocrinology. 2021;111(6):580-585
pubmed: 32615553
Neuroendocrinology. 2017 Apr 8;105(3):201-211
pubmed: 28391265
Endocr Relat Cancer. 2014 Aug;21(4):615-28
pubmed: 25015994
Endocr Relat Cancer. 2017 May;24(5):243-251
pubmed: 28320783
J Endocrinol. 2003 May;177(2):337-41
pubmed: 12740022
World J Surg. 2018 Apr;42(4):1031-1035
pubmed: 29383428
Surgery. 2016 Jan;159(1):336-47
pubmed: 26456125
Curr Opin Endocrinol Diabetes Obes. 2014 Feb;21(1):22-7
pubmed: 24310147
Eur J Cancer. 2016 Jul;62:132-7
pubmed: 27189322
Front Endocrinol (Lausanne). 2018 Dec 04;9:740
pubmed: 30564197
Neuroendocrinology. 2020;110(3-4):198-216
pubmed: 31266019
Clin Chem Lab Med. 2014 Mar;52(3):419-29
pubmed: 24127543
Neuroendocrinology. 2020;110(3-4):185-197
pubmed: 30995665
Nat Rev Gastroenterol Hepatol. 2017 Jun;14(6):331-332
pubmed: 28293026
J Clin Oncol. 2012 Dec 1;30(34):4233-42
pubmed: 23071236
J Natl Compr Canc Netw. 2018 Jun;16(6):693-702
pubmed: 29891520
Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1155-1169
pubmed: 29484451
Cancer Metastasis Rev. 2014 Mar;33(1):353-9
pubmed: 24390486
World J Gastroenterol. 2013 Apr 21;19(15):2348-54
pubmed: 23613628
J Clin Oncol. 2009 Mar 20;27(9):1382-7
pubmed: 19224856
Oncol Lett. 2013 Jan;5(1):63-67
pubmed: 23255895
Int J Biol Markers. 2005 Oct-Dec;20(4):264-8
pubmed: 16398409
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
Lancet Oncol. 2014 Jan;15(1):e8-21
pubmed: 24384494
Biomarkers. 2012 Mar;17(2):186-91
pubmed: 22303881
Neuroendocrinology. 2017;104(2):170-182
pubmed: 27078712
Methods Mol Biol. 2017;1513:83-100
pubmed: 27807832
Clin Cancer Res. 2018 May 1;24(9):2182-2193
pubmed: 29440175
Clin Chem Lab Med. 2007;45(9):1244-50
pubmed: 17663633
Endocr Connect. 2019 Mar 1;:
pubmed: 30865931
J Surg Oncol. 2018 Jul;118(1):37-48
pubmed: 30114319
Oncologist. 2017 Dec;22(12):1451-1462
pubmed: 28642335
Eur J Endocrinol. 2017 Feb;176(2):143-157
pubmed: 27913608
J Thorac Oncol. 2014 Oct;9(10):1443-8
pubmed: 25521397
Neuroendocrinology. 2015;101(1):1-17
pubmed: 25228173
Breast Cancer Res Treat. 2013 Nov;142(2):323-39
pubmed: 24194179
Oncotarget. 2017 Dec 29;9(6):7182-7196
pubmed: 29467960
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Neuroendocrinology. 2014;100(4):265-77
pubmed: 25300695
Pancreas. 2013 May;42(4):557-77
pubmed: 23591432
Endocrinol Metab Clin North Am. 2018 Sep;47(3):485-504
pubmed: 30098712
Ann Transl Med. 2018 Jun;6(12):252
pubmed: 30069454
J Natl Compr Canc Netw. 2015 Jan;13(1):78-108
pubmed: 25583772
Ann Oncol. 2010 Sep;21(9):1794-1803
pubmed: 20139156
Zhonghua Wei Chang Wai Ke Za Zhi. 2017 Mar 25;20(3):357-360
pubmed: 28338171
Endocr Relat Cancer. 2016 Jan;23(1):R27-41
pubmed: 26483424
J Clin Oncol. 2011 Mar 1;29(7):934-43
pubmed: 21263089
Endocr Relat Cancer. 2015 Aug;22(4):561-75
pubmed: 26037279
JAMA Oncol. 2017 Oct 01;3(10):1335-1342
pubmed: 28448665
Cancer. 2009 Apr 15;115(8):1638-50
pubmed: 19197975
Eur J Nucl Med Mol Imaging. 2016 May;43(5):839-851
pubmed: 26596723
Int J Biol Markers. 2005 Jul-Sep;20(3):156-68
pubmed: 16240843
Endocr Connect. 2016 Sep;5(5):174-87
pubmed: 27582247
Nat Rev Clin Oncol. 2016 Nov;13(11):691-705
pubmed: 27273044
Ann Hematol. 2003 Mar;82(3):139-47
pubmed: 12634945
Endocr Relat Cancer. 2014 Apr 28;21(3):R105-20
pubmed: 24351682
Br J Radiol. 2017 Jan;90(1069):20160474
pubmed: 27416998
Semin Cancer Biol. 2015 Feb;30:4-12
pubmed: 24747696
Neuroendocrinology. 2018;107(1):73-90
pubmed: 29566385
World J Gastroenterol. 2011 Nov 7;17(41):4581-9
pubmed: 22147963
Pancreas. 2018 Nov/Dec;47(10):1249-1255
pubmed: 30325865
Oncologist. 2019 Jun;24(6):783-790
pubmed: 30158287